To evaluate the effect of nucleoside-modified VEGFC mRNA-LNP treatment in an experimental disease model, a recently developed46 Diphtheria toxin-inducible genetic secondary lymphedema mouse model was set up and optimized. The gene discussed is VEGFC; the disease is lymphedema.